机译:Gefitinib与vinorelbine Plus顺铂作为阶段II-IIIa(N1-N2)EGFR-突变体NSCLC(佐剂/ CTONG1104)的辅助处理:随机,开放标签,第3期研究
Guangdong Gen Hosp Guangdong Lung Canc Inst Guangzhou 510080 Guangdong Peoples R China;
Fudan Univ Zhongshan Hosp Shanghai Peoples R China;
Zhejiang Canc Hosp Hangzhou Zhejiang Peoples R China;
Fudan Univ Zhongshan Hosp Shanghai Peoples R China;
Hunan Canc Hosp Changsha Hunan Peoples R China;
Qingdao Univ Affiliated Hosp Med Coll Qingdao Peoples R China;
Liaoning Canc Hosp Shenyang Liaoning Peoples R China;
Fujian Med Univ Union Hosp Fuzhou Fujian Peoples R China;
Jilin Prov Tumor Hosp Changchun Jilin Peoples R China;
Jiangsu Canc Hosp Nanjing Jiangsu Peoples R China;
Peking Univ Peoples Hosp Beijing Peoples R China;
Tongji Univ Shanghai Pulm Hosp Shanghai Peoples R China;
Tangdu Hosp Xian Shaanxi Peoples R China;
Peking Univ Hosp 1 Beijing Peoples R China;
Fujian Canc Hosp Fuzhou Fujian Peoples R China;
Beijing Chest Hosp Beijing Peoples R China;
China Med Univ Hosp 1 Shenyang Liaoning Peoples R China;
Beijing Canc Hosp Beijing Peoples R China;
Harbin Med Univ Canc Hosp Harbin Heilongjiang Peoples R China;
Sichuan Univ West China Hosp Chengdu Sichuan Peoples R China;
Sichuan Canc Hosp Chengdu Sichuan Peoples R China;
Northern Jiangsu Peoples Hosp Yangzhou Jiangsu Peoples R China;
Suzhou Univ Affiliated Hosp 1 Suzhou Peoples R China;
Guangdong Gen Hosp Guangdong Lung Canc Inst Guangzhou 510080 Guangdong Peoples R China;
Guangdong Gen Hosp Guangdong Lung Canc Inst Guangzhou 510080 Guangdong Peoples R China;
Guangdong Gen Hosp Guangdong Lung Canc Inst Guangzhou 510080 Guangdong Peoples R China;
Guangdong Gen Hosp Guangdong Lung Canc Inst Guangzhou 510080 Guangdong Peoples R China;
机译:Gefitinib与vinorelbine Plus顺铂作为阶段II-IIIa(N1-N2)EGFR-突变体NSCLC(佐剂/ CTONG1104)的辅助处理:随机,开放标签,第3期研究
机译:Erlotinib对Vinorelbine Plus顺铂作为中国患者阶段IIIA患者辅助治疗突变性非小细胞肺癌(EVAN):随机开放标签,第2期试验
机译:随机期二期试验的三年随访,与顺铂和培育蛋白与顺铂和血管素(治疗研究)进行了早期NSCLC辅助化学疗法
机译:Carboplatin与Carboplatin和多柔比星的相位III比较,用于辅助骨肉瘤的佐剂治疗:临时分析
机译:一项随机多中心开放标签的II期临床研究评估口服长春瑞滨联合顺铂与静脉内长春瑞滨联合顺铂在中国初治为未经化疗或无法切除的转移性非小细胞肺癌患者中的疗效耐受性和药代动力学
机译:II期临床试验的三年随访随访,该试验改善了顺铂和培美曲塞与非铂和长春瑞滨对NSCLC早期辅助化疗的疗效(TREAT研究)